Katrina Perehudoff
Biographic Data
| ID | 4439449 |
|---|---|
| NAME | Katrina Perehudoff |
| GIVEN NAMES | Katrina |
| FAMILY NAME | Perehudoff |
| SIGNATURE | PEREHUDOFF K |
| AFFILIATIONS | University of Amsterdam |
| ORCID | 0000-0003-3958-0244 |
| VERIFIED | Yes |
| TOTAL WORKS | 15 |
| TOTAL CITATIONS | 1 |
| AUTHOR COUNT | 15 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2018 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 1 |
TRIPS flexibilities help change policy and practice to increase access to medicines: Evidence from 2001 to 2024
INTRODUCTION: Millions of people lack access to safe and effective pharmaceuticals because they are unaffordable or unavailable, particularly in 'developing' and 'least-developed' countries (DCs, LDCs), and increasingly in high-income countries (HICs). Management of intellectual property (IP) related to new medicines has a significant impact on access to safe, affordable and effective medicines. The Agreement on Trade-Related Aspects of Intellect…
Accounting for EU external effects: From clinical trials to data colonialism to AI ethics dumping
Against a backdrop of rapidly expanding health artificial intelligence (AI) development, this paper examines how the European Union’s (EU) stringent digital regulations may incentivise the outsourcing of personal health data collection to low- and middle-income countries (LMICs), fuelling a new form of AI ethics dumping. Drawing on parallels with the historical offshoring of clinical trials, we argue that current EU instruments, such as the Gener…
Global ‘side effects’ of the EU’s pharmaceutical reforms and their impact on access to medicines in LMICs
BOX In reforming its pharmaceutical legislation, the European Union (EU) has intentionally leveraged the single market to incentivise companies to plan global antimicrobial access and mitigate antimicrobial resistance caused by medicines manufacturing outside of Europe
Advancing vaccines justice through international regulatory pathways
Vaccines are essential for preventing infectious diseases and promoting population health; however, equitable global access to vaccines remains elusive. Regulatory approval of vaccines is a critical step on the path towards global vaccines justice, yet the resources required can impede timely decision making. Regulatory reliance, where authorities use other agencies' assessments of new vaccines to make local decisions about their benefit-risk pro…
Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (Uncac) Compliance
Pharmaceutical sector corruption undermines patient access to medicines by diverting public funds for private gain and exacerbating health inequities . This paper presents an analysis of UN Convention Against Corruption (UNCAC) compliance in seven countries and examines how full UNCAC adoption may reduce corruption risks within four key pharmaceutical decision-making points: product approval, formulary selection, procurement, and dispensing. Coun…
Ensuring Pharmaceutical Accountability for Human Rights and Access to Medicines: The Dutch Duty of Care Standard Applied to Pharmaceutical Companies
To effectively protect the human right to health, the global accountability gap for pharmaceutical companies regarding access to medicines must be addressed. Pharmaceutical companies have no formal obligations under human rights law; however, they do have responsibilities, and some companies (directly or indirectly) undermine the right to health and equitable access to medicines. We propose that pharmaceutical companies can be held accountable fo…
A pandemic treaty for equitable global access to medical countermeasures: Seven recommendations for sharing intellectual property, know-how and technology
Pandemic, Need to know, Biotechnology and Related Fields, Science, Research, and Medicine, Biomedical Ethics and Regulation
A global social contract to ensure access to essential medicines and health technologies
The COVID-19 pandemic illuminates the need to move away from the current social contract, which focuses on the nation-state’s responsibility for protecting the health of its own population, including by providing essential medicines and health technologies. We argue for embracing a global social contract, which is a governance concept that lays the foundation for how states should act as members of the international community, as regulators of th…
An intersectional human rights approach to prioritising access to Covid-19 vaccines
We finally have a vaccine for the COVID-19 crisis. However, due to the limited numbers of the vaccine, states will have to consider how to prioritise groups who receive the vaccine. In this paper, we argue that the practical implementation of human rights law requires broader consideration of intersectional needs in society and the disproportionate impact that COVID-19 is having on population groups with pre-existing social and medical vulnerabil…
Overriding drug and medical technology patents for pandemic recovery: A legitimate move for high-income countries, too
Compulsory licenses are legal tools to override patent-protection on medicines and medical technologies. Compulsory licenses can help scale up the production and lower prices of patent-protected medicines while still accounting for the patent holder’s interests. Compulsory licensing is making a comeback in high-income countries as a negotiation strategy and a legal tool to remedy high prices and/or supply shortages of medicines and medical techno…
Universal access to essential medicines as part of the right to health: A cross-national comparison of national laws, medicines policies, and health system indicators
BACKGROUND: Access to essential medicines for the world's poor and vulnerable has made little progress since 2000, except for a few specific medicines such as antiretrovirals for HIV/AIDS. Human rights principles written into national law can create a supportive environment for universal access to medicines; however, systematic research and policy guidance on this topic is lacking. OBJECTIVE: To examine how international human rights law and WHO'…
Universal cervical cancer control through a right to health lens: Refocusing national policy and programmes on underserved women
BACKGROUND: Cervical cancer claims 311,000 lives annually, and 90% of these deaths occur in low- and middle-income countries. Cervical cancer is a highly preventable and treatable disease, if detected through screening at an early stage. Governments have a responsibility to screen women for precancerous cervical lesions. Yet, national screening programmes overlook many poor women and those marginalised in society. Under-screened women (called har…
Legislating for universal access to medicines: A rights-based cross-national comparison of UHC laws in 16 countries
Universal health coverage (UHC) aims to ensure that all people have access to health services including essential medicines without risking financial hardship. Yet, in many low- and middle-income countries (LMICs) inadequate UHC fails to ensure universal access to medicines and protect the poor and vulnerable against catastrophic spending in the event of illness. A human rights approach to essential medicines in national UHC legislation could rem…
Realising the right to sexual and reproductive health: Access to essential medicines for medical abortion as a core obligation
BACKGROUND: WHO has a pivotal role to play as the leading international agency promoting good practices in health and human rights. In 2005, mifepristone and misoprostol were added to WHO's Model List of Essential Medicines for combined use to terminate unwanted pregnancies. However, these drugs were considered 'complementary' and qualified for use when in line with national legislation and where 'culturally acceptable'. DISCUSSION: This article …
Access to essential medicines in 195 countries: A human rights approach to sustainable development
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in 194 health systems. We present a follow-up report of eight indicators for access to medicines to serve as a reference point for progress towards SDG Target 3.8 on essential medicines. Data for these eight indicators in 2015 were collected and compared with the 2008 report. Between 2008 and 2015 we observed increased numbers of constitutions recogni…
Legislating for universal access to medicines: A rights-based cross-national comparison of UHC laws in 16 countries
Universal health coverage (UHC) aims to ensure that all people have access to health services including essential medicines without risking financial hardship. Yet, in many low- and middle-income countries (LMICs) inadequate UHC fails to ensure universal access to medicines and protect the poor and vulnerable against catastrophic spending in the event of illness. A human rights approach to essential medicines in national UHC legislation could rem…
Realising the right to sexual and reproductive health: Access to essential medicines for medical abortion as a core obligation
BACKGROUND: WHO has a pivotal role to play as the leading international agency promoting good practices in health and human rights. In 2005, mifepristone and misoprostol were added to WHO's Model List of Essential Medicines for combined use to terminate unwanted pregnancies. However, these drugs were considered 'complementary' and qualified for use when in line with national legislation and where 'culturally acceptable'. DISCUSSION: This article …
Access to essential medicines in 195 countries: A human rights approach to sustainable development
In 2008 the UN Special Rapporteur on the Right to Health published 72 right to health indicators in 194 health systems. We present a follow-up report of eight indicators for access to medicines to serve as a reference point for progress towards SDG Target 3.8 on essential medicines. Data for these eight indicators in 2015 were collected and compared with the 2008 report. Between 2008 and 2015 we observed increased numbers of constitutions recogni…
Legislating for universal access to medicines: A rights-based cross-national comparison of UHC laws in 16 countries
Universal health coverage (UHC) aims to ensure that all people have access to health services including essential medicines without risking financial hardship. Yet, in many low- and middle-income countries (LMICs) inadequate UHC fails to ensure universal access to medicines and protect the poor and vulnerable against catastrophic spending in the event of illness. A human rights approach to essential medicines in national UHC legislation could rem…
Universal access to essential medicines as part of the right to health: A cross-national comparison of national laws, medicines policies, and health system indicators
BACKGROUND: Access to essential medicines for the world's poor and vulnerable has made little progress since 2000, except for a few specific medicines such as antiretrovirals for HIV/AIDS. Human rights principles written into national law can create a supportive environment for universal access to medicines; however, systematic research and policy guidance on this topic is lacking. OBJECTIVE: To examine how international human rights law and WHO'…
Universal cervical cancer control through a right to health lens: Refocusing national policy and programmes on underserved women
BACKGROUND: Cervical cancer claims 311,000 lives annually, and 90% of these deaths occur in low- and middle-income countries. Cervical cancer is a highly preventable and treatable disease, if detected through screening at an early stage. Governments have a responsibility to screen women for precancerous cervical lesions. Yet, national screening programmes overlook many poor women and those marginalised in society. Under-screened women (called har…
An intersectional human rights approach to prioritising access to Covid-19 vaccines
We finally have a vaccine for the COVID-19 crisis. However, due to the limited numbers of the vaccine, states will have to consider how to prioritise groups who receive the vaccine. In this paper, we argue that the practical implementation of human rights law requires broader consideration of intersectional needs in society and the disproportionate impact that COVID-19 is having on population groups with pre-existing social and medical vulnerabil…
Overriding drug and medical technology patents for pandemic recovery: A legitimate move for high-income countries, too
Compulsory licenses are legal tools to override patent-protection on medicines and medical technologies. Compulsory licenses can help scale up the production and lower prices of patent-protected medicines while still accounting for the patent holder’s interests. Compulsory licensing is making a comeback in high-income countries as a negotiation strategy and a legal tool to remedy high prices and/or supply shortages of medicines and medical techno…
A pandemic treaty for equitable global access to medical countermeasures: Seven recommendations for sharing intellectual property, know-how and technology
Pandemic, Need to know, Biotechnology and Related Fields, Science, Research, and Medicine, Biomedical Ethics and Regulation
A global social contract to ensure access to essential medicines and health technologies
The COVID-19 pandemic illuminates the need to move away from the current social contract, which focuses on the nation-state’s responsibility for protecting the health of its own population, including by providing essential medicines and health technologies. We argue for embracing a global social contract, which is a governance concept that lays the foundation for how states should act as members of the international community, as regulators of th…
Legislating for Good Governance in the Pharmaceutical Sector through UN Convention Against Corruption (Uncac) Compliance
Pharmaceutical sector corruption undermines patient access to medicines by diverting public funds for private gain and exacerbating health inequities . This paper presents an analysis of UN Convention Against Corruption (UNCAC) compliance in seven countries and examines how full UNCAC adoption may reduce corruption risks within four key pharmaceutical decision-making points: product approval, formulary selection, procurement, and dispensing. Coun…
Ensuring Pharmaceutical Accountability for Human Rights and Access to Medicines: The Dutch Duty of Care Standard Applied to Pharmaceutical Companies
To effectively protect the human right to health, the global accountability gap for pharmaceutical companies regarding access to medicines must be addressed. Pharmaceutical companies have no formal obligations under human rights law; however, they do have responsibilities, and some companies (directly or indirectly) undermine the right to health and equitable access to medicines. We propose that pharmaceutical companies can be held accountable fo…
Global ‘side effects’ of the EU’s pharmaceutical reforms and their impact on access to medicines in LMICs
BOX In reforming its pharmaceutical legislation, the European Union (EU) has intentionally leveraged the single market to incentivise companies to plan global antimicrobial access and mitigate antimicrobial resistance caused by medicines manufacturing outside of Europe
Advancing vaccines justice through international regulatory pathways
Vaccines are essential for preventing infectious diseases and promoting population health; however, equitable global access to vaccines remains elusive. Regulatory approval of vaccines is a critical step on the path towards global vaccines justice, yet the resources required can impede timely decision making. Regulatory reliance, where authorities use other agencies' assessments of new vaccines to make local decisions about their benefit-risk pro…
TRIPS flexibilities help change policy and practice to increase access to medicines: Evidence from 2001 to 2024
INTRODUCTION: Millions of people lack access to safe and effective pharmaceuticals because they are unaffordable or unavailable, particularly in 'developing' and 'least-developed' countries (DCs, LDCs), and increasingly in high-income countries (HICs). Management of intellectual property (IP) related to new medicines has a significant impact on access to safe, affordable and effective medicines. The Agreement on Trade-Related Aspects of Intellect…
Accounting for EU external effects: From clinical trials to data colonialism to AI ethics dumping
Against a backdrop of rapidly expanding health artificial intelligence (AI) development, this paper examines how the European Union’s (EU) stringent digital regulations may incentivise the outsourcing of personal health data collection to low- and middle-income countries (LMICs), fuelling a new form of AI ethics dumping. Drawing on parallels with the historical offshoring of clinical trials, we argue that current EU instruments, such as the Gener…
Political science (12 works) · Law (10 works) · Medicine (10 works) · Business (9 works) · Pharmaceutical Economics and Policy (9 works) · Human rights (7 works) · Economics (6 works) · Essential medicines (6 works) · Health care (6 works) · Access to medicines (5 works)